Generative Artificial Intelligence (AI) In Drug Discovery Market Landscape 2025: Forecast Data and Growth Strategy Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Generative Artificial Intelligence (AI) In Drug Discovery Market Through 2025?
Recent years have seen a significant expansion in the market size of generative artificial intelligence (AI) used for discovering drugs. It's set to rise from $0.19 billion in 2024 to an impressive $0.25 billion in 2025. This represents a compound annual growth rate (CAGR) of 30.9%. This rapid growth has been driven by various factors, including an increasing occurrence of chronic illnesses, advances in drug discovery and clinical trials, a surge in AI application in healthcare and drug innovation, the growth of the biotech industry, along with increased government backing.

What's the Projected Size of the Global Generative Artificial Intelligence (AI) In Drug Discovery Market by 2029?
The market size of generative artificial intelligence (AI) in drug discovery is anticipated to experience a significant expansion in the coming years, projected to increase to $0.74 billion in 2029 with a compound annual growth rate (CAGR) of 30.6%. The surge in the upcoming period could be attributed to factors such as the rising need for cost-effective drug discovery which encourages the usage of generative AI, developing partnerships among market participants, the surge in computational power, the fusion of generative AI with other nascent technologies, and swift drug advancement. In the forecast period, major trends set to dominate include cutting-edge technologies, blending of experimental biology with generative AI, applying high-throughput screening for fast-tracking drug discovery pipelines, establishment of AI-based platforms for drug repositioning, and increasing uptake of cloud-based AI solutions that facilitate collaborative efforts in drug discovery.

View the full report here:
https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-drug-discovery-global-market-report

Top Growth Drivers in the Generative Artificial Intelligence (AI) In Drug Discovery Industry: What's Accelerating the Market?
The growth of generative AI in the drug discovery market is being boosted by the increasing quantity of clinical trials. These trials, which test the safety and efficiency of novel medical interventions on human volunteers, endeavor to collect data on their compatibility with humans. Medical research advancements, higher disease incidence, regulatory shifts, the international expansion of clinical research, patient education and advocacy, industry rivalry, technological progress, and funding provisions contribute primarily to the rise in clinical trials. Data from these trials contribute to generative AI algorithms, accelerating drug discovery by predicting interactions and novel compound synthesis. This collaboration aids in tailoring medicine to individual needs, enhancing therapeutic effectiveness, bettering patient health outcomes, and transforming the pharmaceutical field. As per ClinicalTrials.gov, a clinical trial registry in the U.S, there were 477,234 worldwide registered clinical trials by the end of 2023, a growth from the 437,512 trials registered during 2022. Hence, the increase in clinical trials is propelling the expansion of generative AI in the drug discovery market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16067&type=smp

What Trends Will Shape the Generative Artificial Intelligence (AI) In Drug Discovery Market Through 2029 and Beyond?
Leading organizations in the generative AI sector within the drug discovery market are innovating advanced AI-empowered tools to hasten the process of drug discovery. The acceleration in drug development is achieved through the usage of AI tools which streamline drug design, discovery, and clinical trials by leveraging predictive analytics and machine learning. These tools notably improve efficiency in several processes such as target identification, compound screening via virtual screening using AI, preclinical development, regulatory adherence, and manufacturing procedures. In a particular case in May 2023, Google Cloud - a cloud computing service from the US provided by Google - launched two novel AI-centric solutions. These solutions, namely the Target and Lead Identification Suite and the Multiomics Suite, are crafted to enhance drug discovery and precision medicine across organizations in the pharmaceutical, biotech, and public sector. While the Target and Lead Identification Suite assists researchers in understanding the functions of amino acids and predicting protein structures, the Multiomics Suite expedites the analysis and comprehension of genomic data, thus simplifying the creation of customized treatments.

What Are the Main Segments in the Generative Artificial Intelligence (AI) In Drug Discovery Market?
The generative artificial intelligence (AI) in drug discovery market covered in this report is segmented -

1) By Type: Small Molecule, Large Molecule
2) By Technology: Deep Learning, Machine Learning, Reinforcement Learning, Molecular Docking, Quantum Computing
3) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutions, Contract Research Organizations (CROs), Other End-Users

Subsegments:
1) By Small Molecule: Drug Design And Optimization, Lead Discovery And Identification, Toxicology Prediction, Molecular Property Prediction, ADMET (Absorption, Distribution, Metabolism, Excretion, And Toxicity) Prediction
2) By Large Molecule: Protein Structure Prediction, Antibody Design, Biologics Optimization, Peptide Design, Biopharmaceutical Discovery And Optimization

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=16067&type=smp

Which Top Companies are Driving Growth in the Generative Artificial Intelligence (AI) In Drug Discovery Market?
Major companies operating in the generative artificial intelligence (AI) in drug discovery market are Bayer AG, NVIDIA Corporation, Merck KGaA, IBM Research, Schrödinger Inc., Valo Health, BenevolentAI, XtalPi Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Exscientia, Atomwise Inc., InveniAI LLC, Healx, Aitia, Cloud Pharmaceuticals Inc., Optibrium, Aiforia, BioSymetrics Inc., Collaborations Pharmaceuticals Inc., MAbSilico, Reverie Labs, Standigm Inc., DeepMatter Group Limited, Variational AI Inc

Which Regions Will Dominate the Generative Artificial Intelligence (AI) In Drug Discovery Market Through 2029?
North America was the largest region in the generative AI in drug discovery market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative artificial intelligence (AI) in drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16067

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.